Polymyositis

Revision as of 18:16, 11 January 2009 by Zorkun (talk | contribs) (→‎Treatment)
Jump to navigation Jump to search
Polymyositis
ICD-10 M33.2
ICD-9 710.4
DiseasesDB 10343
MedlinePlus 000428
eMedicine med/3441  emerg/474
MeSH D017285

WikiDoc Resources for Polymyositis

Articles

Most recent articles on Polymyositis

Most cited articles on Polymyositis

Review articles on Polymyositis

Articles on Polymyositis in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Polymyositis

Images of Polymyositis

Photos of Polymyositis

Podcasts & MP3s on Polymyositis

Videos on Polymyositis

Evidence Based Medicine

Cochrane Collaboration on Polymyositis

Bandolier on Polymyositis

TRIP on Polymyositis

Clinical Trials

Ongoing Trials on Polymyositis at Clinical Trials.gov

Trial results on Polymyositis

Clinical Trials on Polymyositis at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Polymyositis

NICE Guidance on Polymyositis

NHS PRODIGY Guidance

FDA on Polymyositis

CDC on Polymyositis

Books

Books on Polymyositis

News

Polymyositis in the news

Be alerted to news on Polymyositis

News trends on Polymyositis

Commentary

Blogs on Polymyositis

Definitions

Definitions of Polymyositis

Patient Resources / Community

Patient resources on Polymyositis

Discussion groups on Polymyositis

Patient Handouts on Polymyositis

Directions to Hospitals Treating Polymyositis

Risk calculators and risk factors for Polymyositis

Healthcare Provider Resources

Symptoms of Polymyositis

Causes & Risk Factors for Polymyositis

Diagnostic studies for Polymyositis

Treatment of Polymyositis

Continuing Medical Education (CME)

CME Programs on Polymyositis

International

Polymyositis en Espanol

Polymyositis en Francais

Business

Polymyositis in the Marketplace

Patents on Polymyositis

Experimental / Informatics

List of terms related to Polymyositis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [3] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Polymyositis is a type of inflammatory myopathy, related to dermatomyositis and inclusion body myositis. Polymyositis means 'many muscle inflammation'.

Polymyositis is one of a group of muscle diseases known as the inflammatory myopathies, which are characterized by chronic muscle inflammation accompanied by muscle weakness. Polymyositis affects skeletal muscles (those involved with making movement) on both sides of the body. It is rarely seen in persons under age 18; most cases are in adults between the ages of 31 and 60. Slow, but progressive muscle weakness starts in the proximal muscles (muscles closest to the trunk of the body) which eventually leads to difficulties climbing stairs, rising from a sitting position, lifting objects, or reaching overhead. People with polymyositis may also experience arthritis, shortness of breath, difficulty swallowing and speaking, and heart arrhythmias. In some cases of polymyositis, distal muscles (muscles further away from the trunk of the body, such as those in the forearms and around the ankles and wrists) may be affected as the disease progresses. Polymyositis may be associated with collagen-vascular or autoimmune diseases, such as lupus. Polymyositis may also be associated with infectious disorders, such as HIV-AIDS.

Polymyositis tends to become evident in adulthood, presenting with bilateral proximal muscle weakness, often noted in the upper legs due to early fatigue while walking. Sometimes the weakness presents itself by the person being unable to rise from a seated position without help, or inability to raise their arms above their head. The weakness is generally progressive, accompanied by lymphocytic inflammation (mainly cytotoxic T8 lymphocytes). The cause is unknown, but seems to be related to autoimmune factors, genetics, and perhaps viruses. In rare cases, the cause is known to be infectious, associated with the pathogens that cause Lyme disease, toxoplasmosis, and others.[1]

Polymyositis, like dermatomyositis, strikes females with greater frequency than males. The skin involvement of dermatomyositis is absent in polymyositis.

Diagnosis

Diagnosis is fourfold, including elevation of creatine kinase, signs and symptoms, electromyograph (EMG) alteration, and a positive muscle biopsy. Treatment generally involves glucocorticoids, especially prednisone. At present, a number of studies are underway to determine whether patients diagnosed with polymyositis will benefit from newer drugs inhibiting the biologic effects of TNF alpha, such as Infliximab ("Remicade").

Sporadic inclusion body myositis (sIBM): IBM is often confused with (misdiagnosed as) polymyositis and polymyositis that does not respond to treatment is likely IBM. sIBM comes on over months to years, polymyositis comes on over weeks to months. It appears that sIBM and polymyositis share some common features, especially the initial sequence of immune system activation, however, polymyositis does not display the subsequent muscle degeneration and protein abnormalities as seen in IBM. As well, polymyositis tends to respond well to treatments, IBM does not. IBM and polymyositis apparently involve different disease mechanisms than are seen in dermatomyositis.

Treatment

There is no cure for polymyositis, but the symptoms can be treated. Options include medication, physical therapy, exercise, heat therapy (including microwave and ultrasound), orthotics and assisted devices, and rest.

The standard treatment for polymyositis is a corticosteroid drug, given either in pill form or intravenously. Immunosuppressant drugs, such as azathioprine and methotrexate, may reduce inflammation in people who do not respond well to prednisone.

Periodic treatment using intravenous immunoglobulin can also improve recovery.

Other immunosuppressive agents used to treat the inflammation associated with polymyositis include cyclosporine A, cyclophosphamide, and tacrolimus.

Physical therapy is usually recommended to prevent muscle atrophy and to regain muscle strength and range of motion.

Prognosis

The prognosis for polymyositis varies. Most people respond fairly well to therapy, but some have a more severe disease that does not respond adequately to therapies and are left with significant disability.

In rare cases individuals with severe and progressive muscle weakness will develop respiratory failure or pneumonia. Difficulty swallowing may cause weight loss and malnutrition.

References

  1. Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL. Harrison's Principles of Internal Medicine. New York: McGraw-Hill, 2005. ISBN 0-07-139140-1

Template:Diseases of the musculoskeletal system and connective tissue Template:SIB

de:Polymyositis ku:Polîmiyozît he:פולימיוזיטיס fi:Polymyosiitti


Template:WikiDoc Sources